Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Legend Biotech (NASDAQ: LEGN) has announced an upcoming investor event during the 66th ASH Annual Meeting in San Diego.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Legend Biotech (NASDAQ: LEGN) has announced an upcoming investor event during the 66th ASH Annual Meeting in San Diego. The live webcast is scheduled for December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET). CEO Ying Huang and CMO Mythili Koneru will host expert clinicians to discuss updates from the CARTITUDE development program. Investors can access the webcast through a provided weblink or the company's website under Events and Presentation section.
Details
News Market Reaction – LEGN
The recorded move for LEGN in the trading session of this news was -1.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA.
During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinicians as they review the latest updates from the CARTITUDE development program.
Investors and other interested parties may join the live webcast through this weblink or by visiting Legend Biotech’s website under Events and Presentation.
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Mary Ann Ondish
Tel: (914) 552-4625
media@legendbiotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.